73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Review of American newspapers reveals positive coverage of lung cancer screening

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that
Controlling a cancer-associated gene can mimic muscle growth from exercise

Controlling a cancer-associated gene can mimic muscle growth from exercise

byUniversity of ArkansasTranscriptional similarities between human RE recovery and MYC overexpression in mouse plantaris muscle. Credit:EMBO Reports(2024). DOI: 10.1038/s44319-024-00

Controlling a cancer-associated gene can mimic muscle growth from exercise

byUniversity of ArkansasTranscriptional similarities between human RE recovery and MYC overexpression in mouse plantaris muscle. Credit:EMBO Reports(2024). DOI: 10.1038/s44319-024-00
B cells linked to effective cancer immunotherapy

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran
Why lung cancer doesn't respond well to immunotherapy

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att
Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho
More proof that concurrent use of multiple medications leads to adversity for older cancer patients

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,
Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),
Targeted lung cancer drug shows promise in phase I/II clinical trial

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t
Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe
Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK
As cancer deaths decline, access to care remains a challenge in some US communities

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th